Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total		Class A Common Stock	Common stock	Common stock Class A Common Stock	Common stock Class B Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, beginning balance	$ 824,725				$ 0	$ 0	$ 1,497,373	$ (725,648)	$ (705)	$ 53,705
Stockholders' Equity, beginning balance (in shares) at Jan. 31, 2023					94,655,000	56,489,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					10,979,000	(10,979,000)
Issuance of common stock related to vested exercised stock options (in shares)						2,467,000
Issuance of common stock related to vested exercised stock options	22,639						22,639
Issuance of common stock under employee stock purchase plan (in shares)					247,000
Issuance of common stock under employee stock purchase plan	7,751						7,751
Repurchases, net of early exercised stock options (in shares)						(13,000)
Issuance of common stock related to RSUs vested (in shares)					1,663,000
Charitable donation of common stock (in shares)			186,899	188,000
Charitable donation of common stock	8,025		$ 8,000				8,025
Vesting of early exercised stock options	1,030						1,030
Stock-based compensation expense	120,032						122,099			(2,067)
Change in noncontrolling interest ownership							(542)			542
Other comprehensive income (loss)	(558)								2,252	(2,810)
Net income (loss)	(390,462)							(387,707)		(2,755)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2023					107,732,000	47,964,000
Stockholders' Equity, ending balance at Oct. 31, 2023	593,182				$ 0	$ 0	1,658,375	(1,113,355)	1,547	46,615
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, beginning balance	831,240				$ 0	$ 0	1,610,072	(828,197)	1,782	47,583
Stockholders' Equity, beginning balance (in shares) at Jul. 31, 2023					103,432,000	51,178,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					3,621,000	(3,621,000)
Issuance of common stock related to vested exercised stock options (in shares)						407,000
Issuance of common stock related to vested exercised stock options	4,706						4,706
Issuance of common stock related to RSUs vested (in shares)					625,000
Charitable donation of common stock (in shares)			53,510		54,000
Charitable donation of common stock	2,675		$ 2,700				2,675
Vesting of early exercised stock options	221						221
Stock-based compensation expense	41,334						40,740			594
Change in noncontrolling interest ownership							(39)			39
Other comprehensive income (loss)	(639)								(235)	(404)
Net income (loss)	(286,355)							(285,158)		(1,197)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2023					107,732,000	47,964,000
Stockholders' Equity, ending balance at Oct. 31, 2023	593,182				$ 0	$ 0	1,658,375	(1,113,355)	1,547	46,615
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, beginning balance	593,182				0	0	1,658,375	(1,113,355)	1,547	46,615
Stockholders' Equity, beginning balance	$ 617,934	[1]			$ 0	$ 0	1,718,661	(1,149,822)	2,335	46,760
Stockholders' Equity, beginning balance (in shares) at Jan. 31, 2024					114,670,000	42,887,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					23,110,000	(23,110,000)
Issuance of common stock related to vested exercised stock options (in shares)	1,778,000					1,778,000
Issuance of common stock related to vested exercised stock options	$ 17,904						17,904
Issuance of common stock under employee stock purchase plan (in shares)					252,000
Issuance of common stock under employee stock purchase plan	7,932						7,932
Issuance of common stock related to RSUs vested (in shares)					2,323,000
Charitable donation of common stock (in shares)			173,181		173,000
Charitable donation of common stock	8,871		$ 8,900				8,871
Vesting of early exercised stock options	267						267
Stock-based compensation expense	139,263						138,427			836
Change in noncontrolling interest ownership							(409)			409
Other comprehensive income (loss)	(7,602)								(7,331)	(271)
Net income (loss)	(14,346)							(12,130)		(2,216)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2024					140,528,000	21,555,000
Stockholders' Equity, ending balance at Oct. 31, 2024	770,223	[1]			$ 0	$ 0	1,891,653	(1,161,952)	(4,996)	45,518
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, beginning balance	688,004				$ 0	$ 0	1,833,786	(1,191,517)	570	45,165
Stockholders' Equity, beginning balance (in shares) at Jul. 31, 2024					136,462,000	23,963,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					3,255,000	(3,255,000)
Issuance of common stock related to vested exercised stock options (in shares)						847,000
Issuance of common stock related to vested exercised stock options	7,830						7,830
Issuance of common stock related to RSUs vested (in shares)					758,000
Charitable donation of common stock (in shares)			52,940		53,000
Charitable donation of common stock	2,957		$ 3,000				2,957
Vesting of early exercised stock options	78						78
Stock-based compensation expense	48,042						47,002			1,040
Other comprehensive income (loss)	(4,955)								(5,566)	611
Net income (loss)	28,267							29,565		(1,298)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2024					140,528,000	21,555,000
Stockholders' Equity, ending balance at Oct. 31, 2024	770,223	[1]			$ 0	$ 0	1,891,653	(1,161,952)	(4,996)	45,518
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, beginning balance	$ 770,223	[1]			$ 0	$ 0	$ 1,891,653	$ (1,161,952)	$ (4,996)	$ 45,518

[1] (1) As of October 31, 2024 and January 31, 2024, the condensed consolidated balance sheet includes assets of the consolidated variable interest entity, GitLab Information Technology (Hubei) Co., LTD (“JiHu”), of $43.4 million and $47.6 million, respectively, and liabilities of $6.1 million for each period presented. The assets of JiHu can be used only to settle obligations of JiHu and creditors of JiHu do not have recourse against the general credit of the Company. Refer to “Note 11. Joint Venture and Equity Method Investment” for further discussion.